Good post @cub40 I'm very sceptical over the 5 to 10 bucks per...

First 27 Last

Share
Profile

Follow
wop

2,295 Posts.

356

02/08/21

12:26

Post #: 54959756
Share
Originally posted by cub40 ↑

If it is Medgate, which would seem the most likely, it will be interesting to see how Medgate will roll this out across other countries that they operate, including the Philippines, India and the UAE.

It looks like the AI assisted triage tool, which assist in identifying if a patient should be directed to the ResAppDx test, is being rolled out to the Philippines this year (https://www.bworldonline.com/medgate-to-roll-out-ai-assisted-teleconsultation/)

Some interesting stats are mentioned in this article. Medgate are receiving 10,000 calls per day in Switzerland and 500 per day in the Philippines. It shows how much more advanced and mature the telehealth market is in Europe.

Based on these numbers, with respiratory conditions making up between 33%-50% of all telehealth consultations and using the sliding scale of $5-$10 per test, gives a revenue range of $4.29m-$13.00m per year.

Most importantly, the value of this deal is not in the quantum of dollars it will bring in, but

the experience that this would have given the team in understanding the telehealth clinical workflows from an advanced and established player like Medgate player, and

real world clinical validation of ResAppDx within that clinical workflow

Any likely deals in the pipeline with other telehealth players should surface shortly and the time to integrate ResAppDx clinically and technically should only be a fraction of the time it has taken to get Medgate onboard.

Expand

Good post @cub40 I'm very sceptical over the 5 to 10 bucks per use (hope im very wrong) We need to see wording like The company does expect this commercial deal with Medgate to be of a material nature to Resapp and provide considerable revenues going forward.
Last edited by wop: 02/08/21

RAP Price at posting: 4.0¢ Sentiment: None Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

BHP

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

ASX hits all time high out the gate on Friday trades following bullish US inflation data

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Bitcoin investors need to know the risks

MDI

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

NIM

Nimy to raise $1.21M to explore 'newsy' WA targets

IMM

Immutep reports strong response rate from immunotherapies treating carcinomas

SKS

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

AII

Almonty locks in govt agreement for tungsten oxide plant in South Korea

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

There are more pages in this discussion • 78 more messages in this thread...

First 27 Last

Add RAP (ASX) to my watchlist

Good post @cub40 I'm very sceptical over the 5 to 10 bucks per...

Top Stories

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

ASX hits all time high out the gate on Friday trades following bullish US inflation data

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Bitcoin investors need to know the risks

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Nimy to raise $1.21M to explore 'newsy' WA targets

Immutep reports strong response rate from immunotherapies treating carcinomas

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

Almonty locks in govt agreement for tungsten oxide plant in South Korea

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Featured News